Back
First Trust NASDAQ® Cln Edge® GrnEngyETF Vs. Sarepta Therapeutics Industry Stock Comparison
Buy
56
QCLN
First Trust NASDAQ® Cln Edge® GrnEngyETF
Last Price:
35.13
Seasonality Move:
8.24%
Buy
60
SRPT
Sarepta Therapeutics
Last Price:
138.01
Seasonality Move:
14.88%
Buy
56
First Trust NASDAQ® Cln Edge® GrnEngyETF (QCLN)
is a Buy
Is First Trust NASDAQ® Cln Edge® GrnEngyETF a Buy, Sell or Hold?
- The current First Trust NASDAQ® Cln Edge® GrnEngyETF [QCLN] share price is $35.14. The Score for QCLN is 56, which is 12% above its historic median score of 50, and infers lower risk than normal.
- QCLN is currently trading in the 50-60% percentile range relative to its historical Stock Score levels.
- This Score is currently showing a higher than normal reading, suggesting risk levels may be somewhat lower than normal.
Buy
60
Sarepta Therapeutics (SRPT)
is a Buy
Is Sarepta Therapeutics a Buy, Sell or Hold?
- The current Sarepta Therapeutics [SRPT] share price is $137.94. The Score for SRPT is 60, which is 20% above its historic median score of 50, and infers lower risk than normal.
- SRPT is currently trading in the 50-60% percentile range relative to its historical Stock Score levels.
- This Score is currently showing a higher than normal reading, suggesting risk levels may be somewhat lower than normal.
QCLN Stock Price Chart
What is First Trust NASDAQ® Cln Edge® GrnEngyETF's stock price today?
-
The First Trust NASDAQ® Cln Edge® GrnEngyETF share price today is $35.14
Based on the share price being above its 5, 20 & 50 day exponential moving averages, the current trend is considered strongly bullish and QCLN is experiencing slight selling pressure.
SRPT Stock Price Chart
What is Sarepta Therapeutics's stock price today?
-
The Sarepta Therapeutics share price today is $137.94
Based on the share price being above its 5, 20 & 50 day exponential moving averages, the current trend is considered strongly bullish and SRPT is experiencing buying pressure, which is a positive indicator for future bullish movement.
QCLN Technical Analysis
| Chart Indicators | Level | Buy or Sell |
|---|---|---|
| MACD (12, 26): | 0.17 | Buy |
| Relative Strength Index (14 RSI): | 57.77 | Buy |
| Chaikin Money Flow: | -26086 | - |
| Bollinger Bands | Level | Buy or Sell |
|---|---|---|
| Bollinger Bands (25): | (33.26 - 34.64) | Buy |
| Bollinger Bands (100): | (33.18 - 36.08) | Buy |
SRPT Technical Analysis
| Chart Indicators | Level | Buy or Sell |
|---|---|---|
| MACD (12, 26): | -0.37 | Sell |
| Relative Strength Index (14 RSI): | 69.97 | Buy |
| Chaikin Money Flow: | 2429824 | - |
| Bollinger Bands | Level | Buy or Sell |
|---|---|---|
| Bollinger Bands (25): | (110.85 - 129.69) | Buy |
| Bollinger Bands (100): | (119.21 - 142.01) | Buy |
QCLN Moving Averages
| Moving Averages | Level | Buy or Sell |
|---|---|---|
| 8-day SMA: | 34.23 | Buy |
| 20-day SMA: | 33.94 | Buy |
| 50-day SMA: | 34.33 | Buy |
| 200-day SMA: | 34.64 | Buy |
| 8-day EMA: | 34.48 | Buy |
| 20-day EMA: | 34.13 | Buy |
| 50-day EMA: | 34.2 | Buy |
| 200-day EMA: | 35.63 | Sell |
SRPT Moving Averages
| Moving Averages | Level | Buy or Sell |
|---|---|---|
| 8-day SMA: | 116.25 | Buy |
| 20-day SMA: | 117.78 | Buy |
| 50-day SMA: | 122.17 | Buy |
| 200-day SMA: | 130.04 | Buy |
| 8-day EMA: | 121.1 | Buy |
| 20-day EMA: | 119.12 | Buy |
| 50-day EMA: | 122.54 | Buy |
| 200-day EMA: | 126.1 | Buy |
First Trust NASDAQ® Cln Edge® GrnEngyETF Earnings Growth & QCLN Earnings Dates
- Analysts estimate an earnings decrease this quarter of $0.00 per share, a decrease next quarter of $0.00 per share, a decrease this year of $0.00 per share, and a decrease next year of $0.00 per share.
Sarepta Therapeutics Earnings Growth & SRPT Earnings Dates
- Analysts estimate an earnings increase this quarter of $2.75 per share, a decrease next quarter of $0.00 per share, an increase this year of $4.84 per share, and an increase next year of $7.74 per share.
First Trust NASDAQ® Cln Edge® GrnEngyETF Technical Analysis
| Nov 14 | Nov 15 | Nov 18 | Nov 19 | Nov 20 | Nov 21 | Nov 22 | Nov 25 | Nov 26 | Nov 27 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Nov | ||||||||||
| 14 | 15 | 18 | 19 | 20 | 21 | 22 | 25 | 26 | 27 | |
| Technical Analysis: Buy or Sell? | ||||||||||
| 8-day SMA: | ||||||||||
| 20-day SMA: | ||||||||||
| 50-day SMA: | ||||||||||
| 200-day SMA: | ||||||||||
| 8-day EMA: | ||||||||||
| 20-day EMA: | ||||||||||
| 50-day EMA: | ||||||||||
| 200-day EMA: | ||||||||||
| MACD (12, 26): | ||||||||||
| Relative Strength Index (14 RSI): | ||||||||||
| Bollinger Bands (25): | ||||||||||
| Bollinger Bands (100): | ||||||||||
Sarepta Therapeutics Technical Analysis
| Nov 14 | Nov 15 | Nov 18 | Nov 19 | Nov 20 | Nov 21 | Nov 22 | Nov 25 | Nov 26 | Nov 27 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Nov | ||||||||||
| 14 | 15 | 18 | 19 | 20 | 21 | 22 | 25 | 26 | 27 | |
| Technical Analysis: Buy or Sell? | ||||||||||
| 8-day SMA: | ||||||||||
| 20-day SMA: | ||||||||||
| 50-day SMA: | ||||||||||
| 200-day SMA: | ||||||||||
| 8-day EMA: | ||||||||||
| 20-day EMA: | ||||||||||
| 50-day EMA: | ||||||||||
| 200-day EMA: | ||||||||||
| MACD (12, 26): | ||||||||||
| Relative Strength Index (14 RSI): | ||||||||||
| Bollinger Bands (25): | ||||||||||
| Bollinger Bands (100): | ||||||||||